Clinical Trials Logo

Filter by:
NCT ID: NCT05393440 Recruiting - Clinical trials for Uterine Cervical Neoplasms

First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer

CC-OV01
Start date: September 16, 2022
Phase: Phase 1
Study type: Interventional

This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

NCT ID: NCT05393427 Recruiting - Other Solid Tumors Clinical Trials

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Start date: February 15, 2022
Phase: Phase 1
Study type: Interventional

In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be evaluated.

NCT ID: NCT05392868 Recruiting - Clinical trials for Dentine Hypersensitivity

Managing Dentine Hypersensitivity With Silver Diamine Fluoride on Older Adults

Start date: February 1, 2023
Phase: Phase 2
Study type: Interventional

Background: Dentine hypersensitivity is a common oral complaint from older adults. It induces pain, affects oral hygiene practice, limits food choices and negatively affects the quality of life. Silver diamine fluoride (SDF) is a desensitizing agent but well-designed clinical trials are lacking. The objective of this study is to evaluate the effectiveness of SDF in reducing dentine hypersensitivity in older Chinese adults. Methods: This is a double-blinded randomised clinical trial recruiting 166 healthy older adults aged 65 or over after having written consent. A trained calibrated examiner will conduct clinical examination and assess dentine hypersensitive using a blast of compressed air delivered from 3-in-1 syringe. Older adults with a tooth with a self-perceived sensitivity score (SS) of 8 or above will be recruited. They will then be block randomised to receive either 38% SDF solution or 5% potassium nitrate every 4 weeks on the exposed root surface of the most hypersensitive tooth. The visible plaque index, bleeding on probing and probing depth (mm) will be recorded on the most hypersensitive tooth. The same examiner will perform clinical examination and assess the dentine hypersensitivity using the same tools and methods at 4-week and 8-week follow-ups. The examiner and older adults will be blinded to treatment allocation. The primary outcome is the percentage of change in SS before and after intervention at 8 weeks. The secondary outcome will be the percentage of change in VPI before and after intervention at 8 weeks. Clinical significance: It will provide evidence to manage dentine hypersensitivity in older adults in clinical care.

NCT ID: NCT05392712 Recruiting - Clinical trials for Chest Pain, Acute Coronary Syndrome, Myocardial Infarction

Magnetocardiography in the Accurate Identification of Severe Coronary Lesions and Myocardial Necrosis

Start date: May 30, 2022
Phase: N/A
Study type: Interventional

Magnetocardiography (MCG) is a promising noninvasive and accurate method for detecting myocardial ischemia. Although progress has been made in this area, there is a lack of studies using up-to-date examination instruments for the calibration of MCG analysis. This is a prospective single-center study aiming to build accurate analytical models of MCG to detect coronary lesions and myocardial necrosis. Coronary lesions are measured by coronary angiography (CAG) or coronary CTA, and are defined by both the stenosis degree and the computer-simulated fraction flow reserve. Myocardial necrosis is examined and quantified by cardiac MR. Healthy volunteers, chest pain patients who will receive CAG or CTA examination, and patients with acute myocardial infarction will be enrolled in this study.

NCT ID: NCT05392699 Recruiting - Clinical trials for Patients With Advanced Solid Tumors

ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

Start date: May 25, 2022
Phase: Phase 1
Study type: Interventional

Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection. The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.

NCT ID: NCT05392686 Recruiting - Lung Cancer Clinical Trials

PD1 and PARP for Maintenance Therapy in NSLLC

Start date: June 20, 2022
Phase: Phase 2
Study type: Interventional

PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1 plus maintenance PARP for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: respect to progression-free survival (PFS) per RECIST 1.1 by blinded independent clinical review (BICR). Overall survival (OS).

NCT ID: NCT05392426 Recruiting - Clinical trials for Postoperative Complications

Left Ventricular Global Longitudinal Strain and Postoperative Myocardial Injury

Start date: May 30, 2022
Phase:
Study type: Observational

To use left ventricular global longitudinal strain as a means of monitoring myocardial exercise function during anaesthesia in patients with coronary artery disease, to explore the association with the occurrence of postoperative myocardial injury, and to perform a predictive study of postoperative myocardial injury. The study was designed according to a prospective follow-up cohort.

NCT ID: NCT05392413 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody

Start date: August 1, 2022
Phase:
Study type: Observational

200 patients with advanced esophageal cancer who received PD-1 monoclonal antibody treatment would be enrolled in this study. Changes in peripheral blood immune cells before and after treatment would be recorded and used for machine learning to establish a prediction model for the efficacy of PD-1 monoclonal antibody treatment.

NCT ID: NCT05392387 Recruiting - Clinical trials for Hepatitis B Virus Infection

Treatment and Prognosis of Patients With Chronic HBV Infection

Start date: October 25, 2021
Phase:
Study type: Observational [Patient Registry]

Hepatitis B virus (HBV) infection is a major global health issue with 257 million chronically infected individuals. Of note, China has the largest population accounting for one third of the world's infected population. Approximately, about 300 000 people die each year due to the consequences of HBV. In 2016, the World Health Organization (WHO) proposed the goal for elimination of hepatitis B as public health threat by 2030 and China will be a major contributor towards this global goal. Currently, two approved therapeutic strategies are available including pegylated interferon (IFN) or nucleos (t) ide analogues (NA), which could suppress HBV replication and slow disease progression. Here, investigators hope to launch a cohort study to reveal the clinical features relating to therapeutic efficacy of antiviral therapy and the prognosis of patients with differential therapeutic strategies.

NCT ID: NCT05392348 Recruiting - Gut Microbiota Clinical Trials

Human Gut Microbiota and microRNA Expression

Start date: May 25, 2022
Phase: N/A
Study type: Interventional

In this study, stachyose was used as an intervention factor. We will evaluate changes in fecal gut microbiota and miRNA expression profiles in subjects under stachyose intervention